Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
08 02 2022
Historique:
entrez: 7 2 2022
pubmed: 8 2 2022
medline: 22 2 2022
Statut: ppublish

Résumé

Acetaminophen is widely used as first-line therapy for chronic pain because of its perceived safety and the assumption that, unlike nonsteroidal anti-inflammatory drugs, it has little or no effect on blood pressure (BP). Although observational studies suggest that acetaminophen may increase BP, clinical trials are lacking. We, therefore, studied the effects of regular acetaminophen dosing on BP in individuals with hypertension. In this double-blind, placebo-controlled, crossover study, 110 individuals were randomized to receive 1 g acetaminophen 4× daily or matched placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate treatment. At the beginning and end of each treatment period, 24-hour ambulatory BPs were measured. The primary outcome was a comparison of the change in mean daytime systolic BP from baseline to end of treatment between the placebo and acetaminophen arms. One-hundred three patients completed both arms of the study. Regular acetaminophen, compared with placebo, resulted in a significant increase in mean daytime systolic BP (132.8±10.5 to 136.5±10.1 mm Hg [acetaminophen] vs 133.9±10.3 to 132.5±9.9 mm Hg [placebo]; Regular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo; this increases cardiovascular risk and calls into question the safety of regular acetaminophen use in this situation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01997112. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2013-003204-40.

Sections du résumé

BACKGROUND
Acetaminophen is widely used as first-line therapy for chronic pain because of its perceived safety and the assumption that, unlike nonsteroidal anti-inflammatory drugs, it has little or no effect on blood pressure (BP). Although observational studies suggest that acetaminophen may increase BP, clinical trials are lacking. We, therefore, studied the effects of regular acetaminophen dosing on BP in individuals with hypertension.
METHODS
In this double-blind, placebo-controlled, crossover study, 110 individuals were randomized to receive 1 g acetaminophen 4× daily or matched placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate treatment. At the beginning and end of each treatment period, 24-hour ambulatory BPs were measured. The primary outcome was a comparison of the change in mean daytime systolic BP from baseline to end of treatment between the placebo and acetaminophen arms.
RESULTS
One-hundred three patients completed both arms of the study. Regular acetaminophen, compared with placebo, resulted in a significant increase in mean daytime systolic BP (132.8±10.5 to 136.5±10.1 mm Hg [acetaminophen] vs 133.9±10.3 to 132.5±9.9 mm Hg [placebo];
CONCLUSIONS
Regular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo; this increases cardiovascular risk and calls into question the safety of regular acetaminophen use in this situation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01997112. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2013-003204-40.

Identifiants

pubmed: 35130054
doi: 10.1161/CIRCULATIONAHA.121.056015
pmc: PMC7612370
mid: EMS140930
doi:

Substances chimiques

Acetaminophen 362O9ITL9D

Banques de données

ClinicalTrials.gov
['NCT01997112']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

416-423

Subventions

Organisme : British Heart Foundation
ID : FS/16/1/31699
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/13/26/30128
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/4/33541
Pays : United Kingdom

Investigateurs

Morag McCallum (M)
Vanessa Melville (V)
Henry Fok (H)
Jame C McCrae (JC)
Ashish Sule (A)
Thomas M Caparrotta (TM)
Nicholas S Kirkby (NS)
Jane A Mitchell (JA)

Commentaires et corrections

Type : CommentIn

Références

Lancet. 2014 Nov 1;384(9954):1586-96
pubmed: 25064594
Circulation. 2006 Mar 28;113(12):1578-87
pubmed: 16534006
Am J Hypertens. 2018 Nov 13;31(12):1324-1331
pubmed: 30052747
Br J Clin Pharmacol. 2013 Jun;75(6):1396-405
pubmed: 23145789
Arch Intern Med. 1993 Feb 22;153(4):477-84
pubmed: 8435027
Circulation. 2010 Nov 2;122(18):1789-96
pubmed: 20956208
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
Lancet. 2017 Jul 8;390(10090):e21-e33
pubmed: 28699595
Hypertension. 2005 Sep;46(3):500-7
pubmed: 16103274
Drug Ther Bull. 2018 Jun;56(6):69-72
pubmed: 29903753
Blood Press Monit. 2007 Jun;12(3):185-8
pubmed: 17496469
Cochrane Database Syst Rev. 2016 Jun 07;(6):CD012230
pubmed: 27271789
Br J Clin Pharmacol. 2018 Oct;84(10):2218-2230
pubmed: 29863746
EClinicalMedicine. 2019 May 02;11:11-17
pubmed: 31317129
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
J Hypertens. 2013 Jul;31(7):1485-90; discussion 1490
pubmed: 23588196
Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):257-66
pubmed: 15386703
Eur Spine J. 2018 Nov;27(11):2791-2803
pubmed: 29971708
Arch Intern Med. 2005 Mar 14;165(5):490-6
pubmed: 15710786
Ann Intern Med. 1994 Aug 15;121(4):289-300
pubmed: 8037411
Eur Heart J. 2017 Nov 21;38(44):3282-3292
pubmed: 29020251
Arch Intern Med. 2002 Oct 28;162(19):2204-8
pubmed: 12390063

Auteurs

Iain M MacIntyre (IM)

Department of Renal Medicine, Royal Infirmary of Edinburgh, National Health Service Lothian, UK (I.M.M., T.E.F.).

Emma J Turtle (EJ)

Department of Renal Medicine, Royal Infirmary of Edinburgh, National Health Service Lothian, UK (I.M.M., T.E.F.).

Tariq E Farrah (TE)

University/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.

Catriona Graham (C)

Edinburgh Clinical Research Facility (C.G.), University of Edinburgh, UK.

James W Dear (JW)

University/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.

David J Webb (DJ)

University/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH